会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • CHEMICAL LIBRARIES USEFUL FOR DRUG DISCOVERY PROCESSES
    • 化学图书馆有用的药物发现过程
    • WO2003003008A1
    • 2003-01-09
    • PCT/DK2002/000455
    • 2002-06-28
    • 7TM Pharma A/SHÖGBERG, ThomasRIST, ØysteinHJELMENCRANTZ, AndersMOLDT, PeterELLING, Christian, E.SCHWARTZ, Thue, W.GERLACH, Lars, OleHOLST LANGE, Birgitte
    • HÖGBERG, ThomasRIST, ØysteinHJELMENCRANTZ, AndersMOLDT, PeterELLING, Christian, E.SCHWARTZ, Thue, W.GERLACH, Lars, OleHOLST LANGE, Birgitte
    • G01N33/50
    • C07D213/53C07D213/26C07D213/32C07D213/57C07D213/58C07D213/73C07D213/78C07D213/79C07D213/80C07D213/81C07D213/82C07D215/38C07D401/04C07D401/14
    • Use of chemical compounds or selections of chemical compounds (libraries) of the general formula (I): for in vivo methods for testing or validating the physiological importance and/or the therapeutic or pharmacological potential of biological target molecules, notably proteins such as, e.g., receptors and especially 7TM receptors in test animals expressing the biological target molecule with, notably, a silent, engineered metal-ion site. Use of specific metal-ion binding sites of a generic nature in specific biological target molecules such as, e.g. transmembrane proteins wherein the metal-ion binding site is capable of forming a complex with a metal ion is also described. Chemical compounds or libraries suitable for use in methods for improving the in vivo pharmacokinetic behaviour of metal-ion chelates (e.g. the absorption pattern, the plasma half-life, the distribution, the metabolism and/or the elimination of the metal-ion chelates). In order to improve the efficacy of the metal-ion chelates impact on the biological target molecule after administration of the metal-ion chelate in vivo to a test animal it is advantageous e.g. to increase the time period during which the metal-ion chelate is in the circulatory system and/or localised at the target. Metal-ion chelating compounds, which are designed to be suitable for use in a target validation process according to the invention and to libraries of at least two or more of such metal-ion chelating compounds are disclosed.
    • 使用化学化合物或选择通式(I)的化合物(文库):用于测试或验证生物学靶标分子的生理重要性和/或治疗或药理学潜力的体内方法,特别是蛋白质, 例如受体,特别是表达生物靶分子的试验动物中的7TM受体,特别是沉默的工程化金属离子位点。 在特定生物靶分子中使用通用性质的特定金属离子结合位点,例如, 还描述了其中金属离子结合位点能够与金属离子形成络合物的跨膜蛋白。 适合用于改善体内药代动力学的方法的化学化合物或文库是金属离子螯合物(例如吸收图谱,血浆半衰期,分布,代谢和/或金属离子螯合物的消除) )。 为了提高金属离子螯合物在体内将金属离子螯合物给予试验动物后对生物靶分子的影响的功效。 以增加金属离子螯合物在循环系统中和/或定位于靶的时间段。 公开了被设计为适用于根据本发明的目标验证方法和至少两种或更多种这样的金属离子螯合化合物的文库的金属离子螯合化合物。
    • 3. 发明申请
    • TROPANE-DERIVATIVES, THEIR PREPARATION AND USE
    • TROPANE-DERIVATIVES,他们的准备和使用
    • WO1997030997A1
    • 1997-08-28
    • PCT/EP1997000850
    • 1997-02-21
    • NEUROSEARCH A/SSCHEEL-KRÜGER, JorgenMOLDT, PeterWÄTJEN, Frank
    • NEUROSEARCH A/S
    • C07D451/02
    • C07D451/02C07D451/00
    • The present invention discloses compounds of formula (a), (b), (c) or (d), or any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; R is -CH2-X-R', wherein X is O, S or NR", wherein R" is hydrogen, or alkyl and R' is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or -CO-alkyl; R is phenyl which may be substitued one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; 3,4-methylenedioxyphenyl; benzyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; heteroaryl which may be substitued one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; or naphthyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl. The compounds possess valuable pharmaceutical properties as monoamine neurotransmitter, i.e. dopamine, serotonin, noradrenaline, reuptake inhibitors.
    • 本发明公开了式(a),(b),(c)或(d)的化合物或其任何混合物或其药学上可接受的盐; 其中R是氢,烷基,烯基,炔基,环烷基,环烷基烷基或2-羟乙基; R 3是-CH 2 -X-R',其中X是O,S或NR“,其中R”是氢或烷基,R'是烷基,烯基,炔基,环烷基,环烷基烷基或-CO-烷基 ; R 4是可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的苯基; 3,4-亚甲二氧苯基; 可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的苄基。 可以用选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的杂芳基; 或萘基,其可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次。 该化合物具有作为单胺神经递质(即多巴胺,5-羟色胺,去甲肾上腺素,再摄取抑制剂)的有价值的药物性质。
    • 4. 发明申请
    • 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES, THEIR PREPARATION AND USE
    • 8-AZABICYCLO [3.2.1] OCT-2-ENE衍生物,其制备和使用
    • WO1997013770A1
    • 1997-04-17
    • PCT/EP1996004449
    • 1996-10-11
    • NEUROSEARCH A/SMOLDT, PeterSCHEEL-KRÜGER, JorgenOLSEN, Gunnar, M.NIELSEN, Elsebet, Ostergaard
    • NEUROSEARCH A/S
    • C07D451/06
    • C07D451/02C07D451/06
    • A compound having formula (I) or any of its enantiomers of any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; and R is phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; 3,4-methylenedioxyphenyl; benzyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; heteroaryl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; or naphtyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl. The compounds possess valuable pharmaceutical properties as monoamine neurotransmitter re-uptake inhibitors.
    • 具有式(I)的化合物或其任何混合物的任何对映异构体或其药学上可接受的盐; 其中R是氢,烷基,烯基,炔基,环烷基,环烷基烷基或2-羟乙基; 和R 4是可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的苯基; 3,4-亚甲二氧苯基; 可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的苄基。 可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的杂芳基; 或可以被选自卤素,CF 3,CN,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,氨基,硝基,杂芳基和芳基的取代基取代一次或多次的萘基。 该化合物具有作为单胺神经递质再摄取抑制剂的有价值的药物性质。
    • 5. 发明申请
    • METHOD FOR THE PREPARATION OF ESTERS OF ANHYDROECGONINE
    • 制备无机盐的方法
    • WO1996030371A1
    • 1996-10-03
    • PCT/EP1996001277
    • 1996-03-22
    • NEUROSEARCH A/SMOLDT, Peter
    • NEUROSEARCH A/S
    • C07D451/02
    • C07D451/02
    • A process for the preparation of esters of anhydroecgonine having formula (I), any of its enantiomers or any mixture thereof, or a salt thereof, wherein R is alkyl, or optionally substituted aryl, or arylalkyl; comprising the step of reacting a compound of formula (II), any of its enantiomers or any mixture thereof, or a salt thereof, wherein R is hydrogen, alkyl-CO-, or optionally substituted aryl-CO-, or arylalkyl-CO-; with an alcoholate RO , M wherein R is as defined above and M is a counter ion, followed by isolation of the resulting compound either as the base or, if desired, in the form of a salt thereof.
    • 一种制备具有式(I)的脱氢莽吉因酯,其任何对映异构体或其任何混合物或其盐的方法,其中R为烷基或任选取代的芳基或芳基烷基; 包括使式(II)化合物,其任何对映体或其任何混合物或其盐反应的步骤,其中R 1是氢,烷基-CO-或任选取代的芳基-CO-或芳基烷基 -CO-; 其中R为如上定义的并且M +为抗衡离子,随后分离所得化合物作为碱或如果需要,以盐的形式分离 它们。
    • 6. 发明申请
    • 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY
    • 具有神经营养活性的1-(4-哌啶基) - 苯并咪唑
    • WO1997040035A1
    • 1997-10-30
    • PCT/EP1997002011
    • 1997-04-21
    • NEUROSEARCH A/SMOLDT, PeterDAHL, Bjarne, HugoDREJER, JorgenAXELSSON, Oskar
    • NEUROSEARCH A/S
    • C07D401/04
    • C07D401/04
    • The present invention discloses compounds of formula (I) wherein the dotted bonds are optional extra bonds allowing any tautomeric isomers compatible with substituents X and R ; R is non-existing, hydrogen, or alkyl; X is O, S, imino, alkoxy, alkylthio, or amino; R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, acyl, acylalkyl, alkoxyalkyl, dialkoxyalkyl, or phenylalkyl which may be substituted with alkyl, halogen, amino, nitro or cyano; and R , R , R and R independently of each other are hydrogen, halogen, amino, nitro, CN, CF3, COOH, COO-alkyl, alkyl, acyl, alcoxy, -(CH2)n, -OH wherein n is 0, 1, 2 or 3; -(CH2)m-O-alkyl wherein m is 0, 1, 2 or 3; -(CH2)p-O-acyl wherein p is 0, 1, 2 or 3; or a pharmaceutically acceptable addition salt thereof. The compounds are useful as pharmaceuticals, for example, in the treatment of traumatic lesions of peripheral nerves, the medulla, and/or the spinal cord, cerebral ischaemic neuronal damage, neuropathy and especially peripheral neuropathy, dementia, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, or any other neurodegenerative disease.
    • 本发明公开了式(I)的化合物,其中虚线键是任选的额外键,允许任何与取代基X和R 3相容的互变异构体; R 3不存在,氢或烷基; X是O,S,亚氨基,烷氧基,烷硫基或氨基; R 1是氢,烷基,烯基,炔基,环烷基,环烷基烷基,酰基,酰基烷基,烷氧基烷基,二烷氧基烷基或可被烷基,卤素,氨基,硝基或氰基取代的苯基烷基; R 4,R 5,R 6和R 7彼此独立地为氢,卤素,氨基,硝基,CN,CF 3,COOH,COO-烷基,烷基,酰基,烷氧基, (CH 2)n,-OH,其中n为0,1,2或3; - (CH 2)m -O-烷基,其中m为0,1,2或3; - (CH 2)p -O-酰基,其中p为0,1,2或3; 或其药学上可接受的加成盐。 该化合物可用作药物,例如用于治疗周围神经,髓质和/或脊髓的创伤性损伤,脑缺血性神经元损伤,神经病变,特别是周围神经病变,痴呆,阿尔茨海默病,亨廷顿病,帕金森病 疾病,肌萎缩性侧索硬化或任何其他神经变性疾病。